25th Annual San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 10-14 December 2002 update on preclinical and translational research

Breast Cancer Research

Volumn 5, Issue 2, 2003, Pages 109-112

  Head, Julia E ^a   Ring, Alistair ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

BRCA 1 2; cDNA microarray; Growth factor pathways; Prognostic and predictive markers; Proteomics

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR; ESTROGEN RECEPTOR; GEFITINIB; GROWTH FACTOR; MITOGEN ACTIVATED PROTEIN KINASE; ONCOPROTEIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN KINASE B; SOMATOMEDIN; TAMOXIFEN; UROKINASE;

BREAST CANCER; CANCER GENETICS; CANCER MORTALITY; CANCER RESEARCH; CANCER SUSCEPTIBILITY; CONFERENCE PAPER; CONTINUING EDUCATION; DISEASE MARKER; ENDOCRINOLOGY; ENZYME INHIBITION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; IN VITRO STUDY; MASS SPECTROMETRY; PHENOTYPE; PREDICTION; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN PHOSPHORYLATION; PROTEOMICS; SIGNAL TRANSDUCTION; SYMPOSIUM; TUMOR XENOGRAFT; UNITED STATES;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; FEMALE; GENOMICS; GROWTH SUBSTANCES; HUMANS; PROTEOME; SIGNAL TRANSDUCTION;

EID: 0037235236     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr575     Document Type: Conference Paper

References (9)

1. Ring A, Head JE: 25th Annual San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 10-14 December 2002: Update on clinical research. Breast Cancer Res 2003, 5:113-116.
2. Massarweh S, Shou J, DiPietro M, Mohsin SK, Hilsenbeck SG, Wakeling AE, Brown PH, Osborne CK, Schiff R: Targeting the epidermal growth factor receptor pathway improves the anti-tumour effect of tamoxifen and delays acquired resistance in a xenograft model of breast cancer. Breast Cancer Res Treat 2002, 76(Suppl 1):A18.
3. Wilson LLL, Vlahou A, Gregory BW, Perry R, McGaughey DS, Semmes OJ, Wright, Jr. GL, Laronga C: A blood test for breast cancer detection. Breast Cancer Res Treat 2002, 76(Suppl 1): A23.
4. Bjohle J, Pawitan Y, Skoog L, Shaw P, Amler L, Humphreys K, Huang F, Egyhazi S, Borg A-L, Hagerstrom T, Wedren S, Sandelin K, Hall P, Bergh J: Microarray studies on a population based breast cancer cohort - search for gene profiles with prognostic and predictive value. Breast Cancer Res Treat 2002, 76 (Suppl 1):A1.
5. Ragaz J, Lippman M, Van Rijn M, Brodie A, Nielsen T, Hsu F, Huntsman D, Hayes M, Dunn S, Cheang M, Sledge G, Chia S, Harris A, Bajdik C, Spinelli J, Speers C, Hayes D, Gilks B: Survival impact of HER2/Neu, Cox-2, urokinase plasminogen activator (UPA), cytokeratin 17/5, and other markers with long-term outcome of early breast cancer. Report from the British Columbia Tissue Micro-Array Project (BCTMAP). Breast Cancer Res Treat 2002, 76(Suppl 1):A2.
6. Allred DC, Bryant J, Land S, Paik S, Fisher E, Julian T, Margolese R, Smith R, Mamounas T, Osborne CK, Fisher B, Wolmark N: Estrogen receptor expression as a predictive marker of the effectiveness of tamoxifen in the treatment of DCIS: Findings from the NSABP Protocol B-24. Breast Cancer Res Treat 2002, 76(Suppl 1):A30.
7. Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH: Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999, 353:1993-2000.
8. Harbeck N, Kates RE, Look MP, Klijn JGM, Schmitt M, Foekens JA: Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to uPA and PAI-1 (n = 3424). Breast Cancer Res Treat 2002, 76(Suppl 1): A7.
9. Rebbeck TR, Lynch HT, Neuhausen SL, Narod SA, Van't Veer L, Garber JE, Evans G, Isaacs C, Daly MB, Matloff E, Olopade OI, Weber BL: Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.